ABVC BioPharma (ABVC) Competitors $1.77 -0.08 (-4.32%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.80 +0.03 (+1.75%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. PROC, ANIX, IVVD, SAVA, BYSI, GNLX, ENTX, TCRX, HLVX, and IOBTShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Procaps Group (PROC), Anixa Biosciences (ANIX), Invivyd (IVVD), Cassava Sciences (SAVA), BeyondSpring (BYSI), Genelux (GNLX), Entera Bio (ENTX), TScan Therapeutics (TCRX), HilleVax (HLVX), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Its Competitors Procaps Group Anixa Biosciences Invivyd Cassava Sciences BeyondSpring Genelux Entera Bio TScan Therapeutics HilleVax IO Biotech ABVC BioPharma (NASDAQ:ABVC) and Procaps Group (NASDAQ:PROC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability. Is ABVC or PROC more profitable? Procaps Group has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. Procaps Group's return on equity of 0.00% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharma-1,619.65% -104.94% -56.81% Procaps Group N/A N/A N/A Which has better earnings and valuation, ABVC or PROC? Procaps Group has higher revenue and earnings than ABVC BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$508.38K59.12-$10.52M-$0.13-13.62Procaps Group$409.92M0.26$42.54MN/AN/A Which has more volatility and risk, ABVC or PROC? ABVC BioPharma has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Does the media favor ABVC or PROC? In the previous week, ABVC BioPharma had 1 more articles in the media than Procaps Group. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for Procaps Group. ABVC BioPharma's average media sentiment score of 1.87 beat Procaps Group's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Overall Sentiment ABVC BioPharma Very Positive Procaps Group Neutral Do insiders & institutionals believe in ABVC or PROC? 11.4% of ABVC BioPharma shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by company insiders. Comparatively, 19.9% of Procaps Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer ABVC or PROC? Procaps Group received 3 more outperform votes than ABVC BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformABVC BioPharmaN/AN/AProcaps GroupOutperform Votes337.50% Underperform Votes562.50% SummaryProcaps Group beats ABVC BioPharma on 7 of the 12 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.06M$6.86B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E Ratio-2.068.4326.6419.64Price / Sales59.12262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book1.746.536.964.60Net Income-$10.52M$143.25M$3.23B$248.06M7 Day Performance14.94%0.17%-1.05%-0.87%1 Month Performance21.23%11.94%8.65%3.58%1 Year Performance106.05%3.76%33.67%14.04% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.5481 of 5 stars$1.77-4.3%N/A+110.9%$30.06M$508.38K-2.0630Positive NewsGap DownPROCProcaps GroupN/A$0.95-40.3%N/A-63.0%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeANIXAnixa Biosciences3.3734 of 5 stars$3.32-2.4%$9.00+171.1%+22.8%$106.94M$210K-8.515Analyst ForecastGap UpHigh Trading VolumeIVVDInvivyd3.7667 of 5 stars$0.89-8.0%$5.85+556.6%-53.4%$106.89M$36.69M-0.45100Positive NewsGap DownSAVACassava Sciences4.2628 of 5 stars$2.18+1.2%$54.50+2,405.7%-89.7%$105.55MN/A-1.5830Positive NewsBYSIBeyondSpringN/A$2.56+15.8%N/A+11.6%$103.41M$1.88M0.0080Positive NewsGap DownHigh Trading VolumeGNLXGenelux1.1936 of 5 stars$2.71-0.2%$17.75+556.2%+28.6%$102.07M$8K-2.8510Analyst UpgradeENTXEntera Bio1.8424 of 5 stars$2.21+4.2%$10.00+352.5%-10.6%$100.45M$223K-8.5020Short Interest ↑TCRXTScan Therapeutics3.7306 of 5 stars$1.77-0.3%$7.80+341.9%-82.8%$99.88M$4.42M-1.67100Positive NewsGap UpHLVXHilleVax3.2332 of 5 stars$1.98-3.2%$3.00+51.9%-87.5%$99.53MN/A-0.6420Positive NewsIOBTIO Biotech4.0046 of 5 stars$1.49-3.9%$9.33+526.4%+5.5%$98.16MN/A-1.0930Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Procaps Group Competitors Anixa Biosciences Competitors Invivyd Competitors Cassava Sciences Competitors BeyondSpring Competitors Genelux Competitors Entera Bio Competitors TScan Therapeutics Competitors HilleVax Competitors IO Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s worst nightmareThe President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
